Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 Marzo 2023 - 2:30PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the
“Company”), the developer of the Next Generation Chemotherapy drugs
that will provide a better safety-efficacy profile than their
widely used FDA-approved counterparts, today announced that the
Company’s President & CEO, Dr. David Young, will present
virtually at the Oppenheimer 33rd Annual Healthcare Conference
on March 14, 2023 at 12:00 PM Eastern. The company is looking
forward to sharing its progress on key programs and upcoming data
milestones.
A live webcast of the presentation will be
available to all interested parties on the Investor Relations
section of Processa’s website at:
https://www.processapharmaceuticals.com/investors. A replay of the
event will be available on the same webpage following its
conclusion.
To set up 1X1 meetings with management, please
contact your Oppenheimer representative.
About Processa Pharmaceuticals,
Inc.
The mission of Processa is to develop the Next
Generation Chemotherapy drugs that will provide a better
safety-efficacy profile than their FDA-approved counterparts. These
FDA-approved drugs are some of the most widely used chemotherapy
drugs for treating various types of cancers. The Company uses its
Regulatory Science Approach to develop these drugs in order to
achieve high-value milestones effectively and efficiently.
Processa's three Next Generation Chemotherapy oncology treatment
programs are: Next Generation Capecitabine (PCS6422 and
Capecitabine to treat metastatic colorectal, gastrointestinal,
breast, pancreatic, and other cancers), Next Generation Gemcitabine
(PCS3117 to treat pancreatic, lung, ovarian, breast, and other
cancers), and Next Generation Irinotecan (PCS11T to treat lung,
colorectal, gastrointestinal, pancreatic, and other cancers).
For more information, visit our website
at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information:
Michael Floyd(301) 651-4256mfloyd@processapharma.com
Patrick Lin(925) 683-3218plin@processapharma.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024